Green tea as a safe alternative approach for nonalcoholic fatty liver treatment: A systematic review and meta‐analysis of clinical trials

Citations Over TimeTop 10% of 2018 papers

Abstract

This study aimed to evaluate the efficacy of green tea supplementation on nonalcoholic fatty liver disease treatment. Electronic databases, including PubMed, Scopus, Web of Science, and Google Scholar, were systematically searched up to October 30, 2017, to identify eligible trials based on the inclusion criteria. The effect size was presented as mean difference with 95% confidence intervals (CI). The meta-analysis of data from four studies indicated significant effects of green tea supplementation in altering alanine aminotransferases (-12.81 U/L; 95% CI: -18.17 to -7.45) and aspartate aminotransferases (-10.91 U/L; 95% CI: -19.66 to -2.17) blood concentrations. Likewise, a favorable effect of green tea administration was observed on body mass index (-2.08 kg/cm2 ; 95% CI: -2.81 to -1.36), triacylglycerol (-31.87 mg/dl; 95% CI: -40.62 to -23.12), total cholesterol (-27.57 mg/dl; 95% CI: -36.17 to -18.98), and low-density lipoprotein cholesterol (-14.15 mg/dl; 95% CI: -23.69 to -4.60), whereas no significant effect was detected on high-density lipoprotein cholesterol concentrations (7.41 mg/dl; 95% CI: -1.49 to 16.30) and homeostasis model assessment of insulin resistance (-4.06; 95% CI: -10.22 to 2.09). This systematic review and meta-analysis of available trials suggests that there are potential benefits of green tea supplementation on nonalcoholic fatty liver disease.

Related Papers

• → Nonalcoholic fatty liver disease remission in men through regular exercise(2018)17 cited
• → RETRACTION: Leukocyte cell-derived chemotaxin 2 affects nonalcoholic fatty liver disease(2020)1 cited
• [Nutrition mistakes in patients with nonalcoholic fatty liver disease and the ways of correction].(2012)
• A study on the role of serum Retinol Binding Protein 4 in nonalcoholic fatty liver disease(2012)
• The change of serum vaspin level in elderly type 2 diabetic patients with nonalcoholic fatty liver disease(2011)